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SUMMARY: T-level downstaging and complete pathologic respon-
se after preoperative long-term radiochemotherapy for locally ad-
vanced rectal cancer.
J. JONAS, E. MORONI, A. CAVALLARO, M. COLASANTI, 
M.-L. SAUTTER-BIHL, H. FRENZEL, B. LOHE, R. BÄHR
Advantages of neoadjuvant chemoradiotherapy for locally ad-
vanced carcinoma of the middle and the lower third of the rectum
are downstaging and downsizing of the tumor. Results of patholo-
gic results are affected by post-treatment tissue changes and may in-
fluence the choice of surgical procedure.
Forthy-three consecutive patients (27 male, 16 female; mean
age 64 years) were operated after receiving a long-term chemora-
diotherapy during a period of 16 months. The data of initial sta-
ging procedure (high resolution magnetic resonance imaging) and
results of pathological examination of the surgical specimens were
analyzed. Regression of tumor was assessed by the absence of vital
tumor cells and the post-treatment fibrotic tissue alterations.
Regression of tumor size was seen in 42/43 patients leading to
an improved T-stage in 27 patients. R0-resection was possible in all
cases, although there was a perirectal tumor infiltration to less than
2 mm to circumference of the surgical specimen in 2 cases and
unexpected small liver metastasis in 5 cases. Complete remission ra-
te was 23.3% (10 cases).
Detecting small amounts of vital tumor cells in altered tissue
after chemoradiotherapy is a major problem of pathological exami-
nation procedure and should be taken into consideration by the
surgeons. The choice of operation (resection vs. abdominoperineal
extirpation vs. local excision) should be committed to the initial
imaging procedure and not to any restaging procedure after
neoadjuvant chemoradiotherapy. 
RIASSUNTO: Downstaging e risposta patologica completa dopo ra-
diochemioterapia neoadiuvante protratta in pazienti con carcino-
ma del retto localmente avanzato.
J. JONAS, E. MORONI, A. CAVALLARO, M. COLASANTI, 
M.-L. SAUTTER-BIHL, H. FRENZEL, B. LOHE, R. BÄHR
I vantaggi della radiochemioterapia neoadiuvante in pazienti affet-
ti da cancro localmente avanzato del terzo medio e inferiore del retto con-
sistono nella sottostadiazione e nella riduzione delle dimensioni della mas-
sa tumorale. I rilievi istopatologici risentono però dei cambiamenti tissu-
tali post-trattamento e possono influenzare la scelta della procedura chi-
rurgica.
Quarantatre pazienti consecutivi (27 maschi e 16 femmine; età me-
dia 64 anni) sono stati sottoposti a intervento chirurgico dopo aver rice-
vuto radiochemioterapia neoadiuvante per un periodo di 16 mesi. I dati
della prima procedura di staging (risonanza magnetica nucleare ad alta
risoluzione) e i risultati dell’esame istopatologico sul pezzo operatorio sono
stati analizzati. La regressione del tumore è stata definita come assenza di
cellule tumorali vitali e di alterazioni fibrotiche tissutali post trattamento.
Abbiamo osservato una riduzione delle dimensioni della massa tu-
morale in 42 dei 43 pazienti analizzati, con un downstaging in 27 di
essi. In tutti i pazienti è stato possibile praticare  una  resezione R0, seb-
bene siano state rilevate un’infiltrazione peritumorale inferiore a 2 mm
di diametro all’esame istologico in 2 casi e metastasi epatiche di piccole
dimensioni in 5 casi. La percentuale di remissione completa è stata del
23,3% (10 casi).
Rintracciare piccoli aggregati di cellule tumorali vitali nel contesto
di tessuti alterati dalla radiochemioterapia è il principale problema del-
l’esame istologico e dovrebbe essere preso in considerazione dai chirurghi.
La scelta dell’intervento (resezione vs. amputazione addomino-perinea-
le vs. escissione locale) dovrebbe essere guidata dalla procedura di staging
iniziale e non dal restaging effettuato dopo la radiochemioterapia.
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Introduction
Neoadiuvant chemoradiotherapy (nCRT) is consi-
dered one of the standard treatment modalities for lo-
cally advanced rectal cancer of the middle and the
lower third. Residual tumor after surgical therapy of
rectal cancer, lymph node involvement and grade of
tumor infiltration are important prognostic factors.
Potential advantages of nCRT are downsizing and
downstaging of the tumor. 
Tumor response can effect surgical treatment, al-
lowing a higher percentage of sphincter-saving proce-
dures. Additional advantages are the reduction of acu-
te toxicity by avoiding radiation to the neo-rectum
and increases efficacy by irradiating well-oxygenated
tissues. In addition, it introduces systemic therapy ear-
lier, when metastatic burden is the smallest (1). En-
couraging results in terms of local recurrence and sur-
vival have been reported with either observation or a
non radical approach (2, 3). 
Pathologic examination of surgical specimen after
nCRT is made more difficult by the induced tissue
changes. Histological results after nCRT may have di-
rect influence on the surgeons choice of operation.
Patients and methods
Patients. We studied 43 consecutive patients (with biopsy-
proven adenocarcinoma) with a mean age 64 years (range 36-80)
who had undergone surgical resection of a carcinoma of the midd-
le and distal third of the rectum following preoperative chemora-
diotherapy, between January 2004 and November 2005. Patients
(27 male, 16 female) underwent chest X-ray, abdominal/pelvic
magnetic resonance imaging (MRI), and a transrectal ultrasound
(EUS) as a part of their preoperative staging.
Neoadjuvant chemoradiotherapy. Only those patients with
T3/T4 or lymph node positive T2 tumors received nCRT. Patients
were administered 50,4 Gy irradiation (3 fields) in 2 Gy-fractions
over a five-week period. Radiotherapy was delivered by a linear ac-
celerator using 6-10 MV photons and a 3- or 4-field technique
with individually shaped portals and daily fractions of 1.8 Gy on
5 consecutive days per week. Prescribed total dose to the true pel-
vis was 50.4 Gy with a small-volume boost to the primary tumor
of 5.4-9 Gy. The planning target volume was defined from
CT/MRI images and included all identified disease and locoregio-
nal lymph nodes up to the level of the fifth vertebra. During days
1-5 and days 29-33 of radiotherapy, 5-fluorouracil (5-FU) was gi-
ven at a dose of 1000 mg/m2/d (maximum 1800 mg) as 120 h con-
tinuous infusion. Cases of severe hematological or gastrointestinal
toxicity (grade 3 and higher) were not seen.
Surgery. Surgery was performed at approximately six-week in-
tervals following completion of neoadjuvant treatment and a reas-
sessment staging examination for resectability by EUS and MRI.
All patients were prepared for surgical procedure with standard
mechanical bowel preparation, having been given antibiotics pe-
rioperatively. Dissection was performed in the mesorectal plane
down to the pelvic floor according to the standards of total meso-
rectal excision. The essence of surgical technique of total mesorec-
tal excision is preparation under direct vision of the avascular pla-
ne between the mesorectum and the surrounding parietal tissues
right down to the distal part of the pelvis. The excised specimen
includes the whole posterior, distal and lateral mesorectum out to
the plane of the inferior hypogastric plexus, which are carefully
preserved. Anteriorly it includes the intact Denonvilliers’ fascia
and the peritoneal reflection. The characteristic bilobed encapsula-
ted appearance of the intact mesorectum posteriorly and distally
reflects the contours of the pelvic floor and the midline anococcy-
geal raphe. The ideal specimen has a smooth unbroken surface.
This is achieved by meticulous sharp dissection in the avascular
plane surrounding the mesorectum.
Standard surgical procedure was anterior resection of rectum
with a covering stoma in 33 patients (76.7%). Ten patients un-
derwent an abdominoperineal resection (23.3%). No Hartmann’s
procedure was necessary in any case. Patients retained their tempo-
rary stoma following anterior resection until a satisfactory contra-
st enema or rectoscopic control had been performed 3 months la-
ter.
Pathological examination. The surgical specimens were exa-
mined histologically and the regression grade quantified as propo-
sed by Dworak and Wittekind (4, 32). Classes of grading are listed
in Table 1. Pathological staging was undertaken according to the
TNM classification and the pathological extent of maximal extra-
mural spread in millimeters and the distance of tumor to the nea-
rest circumferential resection margin.
If no macroscopic tumor was seen in the pathologic specimen,
multiple sections were prepared, having blocked the entire region
of scarring. Sections were cut at several levels and examined meti-
culously to identify any residual foci of adenocarcinoma. Results
are expressed in terms of T stage, N stage and regression grade. 
Results
Localization of tumor. Rectal carcinoma was loca-
lized in 18 cases (41.9%) in lower third (-7 cm from
anal verge) and in 25 cases (58.1%) in the middle
third of rectum (-14 cm from the anal verge).
MRI-staging. Results of initial MRI-staging are
presented in Figure 1. The majority of tumors
(79.1%) was staged as T3-tumors (n=34), 16.3%
(n=7) were T4-tumors and 4,6% T2-tumors (n=2),
both cases with suspected nodal involvement on ima-
ging procedure. EUS was performed as additional sta-
ging procedure in 38 patients; the results of EUS con-
66
J. Jonas e Coll.
TABLE 1 - QUANTITATIVE REGRESSION OF DWORAK
ET AL. (4) AND WITTEKIND ET AL. (32) USED IN
THIS SERIES.
Grading
no tissue changes
regression <25% of tumor
regression <50% of tumor
regression >50% of tumor
complete regression
1
2
3
4
5
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firmed the MRI staging results in 89.2%. MRI-crite-
ria of suspected nodal involvement were described in
81.4% (n=35).
Regression. The distribution of T-stage and N-sta-
ge determined by histological examination is shown in
Figure 2. Tumor regression was observed in 42/43 ca-
ses (97.7%) in comparison to the results of initial MRI
staging (Table 2). Only one tumor classified as T2-tu-
mor in MRI was a T3-tumor at the final microscopi-
cal examination. All other tumors decreased in size
more than 25%, 23/43 more than 50% and in 10 ca-
ses no vital tumor cells were seen any more. This
means a complete remission rate of 23.3%. In 42/43
cases the distance between tumor infiltration and late-
ral circumference of the surgical specimen was more
than 2 mm. There was no infiltration of circumferen-
cial fascia, corresponding to a R1 situation, after sur-
gical treatment
T-staging. The changes of tumor infiltration ex-
pressed as T-stage in comparison to the definitive
pathological examination are listed in Table 3. In 27
cases tumor downstaging was achieved by nCRT. One
T2-tumor at initial MRI was categorized as T3-tumor
microscopically after surgery. No complete regression
or improvement of T-stage was seen in this T2-group.
Nodal involvement. MRI criterions suspicious for
lymph node involvement were described in 34/43 cases
(79%) (Tab. 4). After nCRT only 10 cases with lymph
node metastases were identified at pathologic examina-
tion. All cases except 1 were correctly diagnosed by ini-
tial MRI. No lymph node involvement was found in
76.4%. That means in summary a N-level-downsta-
ging in 25 cases and a N-level-upstaging in 1 case in
comparison to the results of initial MRI-staging.
TABLE 2 - HISTOLOGIC REGRESSION GRADING
FOUND IN 43 PATIENTS AFTER NEOADJUVANT
CHEMORADIOTHERAPY.
Grading T4 T3 T2
5
4
3
Total
43%
43%
14%
21%
58%
21%
7 
19  
7 
0 
1  
2
Fig. 1 - Distribution of T-stage and N-stage in initial magnetic resonance
imaging procedure.
Fig. 2. Distribution of histological T- and N-stage after neoadjuvant che-
moradiotherapy.
0%
33%
67%
3 
3  
1 
7 33 3
TABLE 3 - COMPARISON OF T-STAGE OF INITIAL MA-
GNETIC RESONANCE IMAGING AND PATHOLOGIC
EXAMINATION AFTER NEOADJUVANT CHEMORA-
DIOTHERAPY.
MRI-stage
Histological stage
T4
0 
0
0
T3
3 
14
1
T2
1 
9
1
T1
0 
4
0
T0
3 
7
0
TABLE 4 - COMPARISON OF N-STAGE OF INITIAL MA-
GNETIC RESONANCE IMAGING AND PATHOLOGIC
EXAMINATION AFTER NEOADJUVANT CHEMORA-
DIOTHERAPY.
MRI
N+
2 
25
7
N-
0
9
0
T2
T3
T4
N+
0 
9
1
N-
3 
24
6
Histology
T4
T3
T2
Discussion
Accurate pretreatment staging is imperative with
the use of preoperative multimodal treatment. 
MRI is commonly used in staging of pelvic mali-
gnancies because of its fine resolution of all anatomi-
cal details (6). Anatomy of the inferior hypogastric
plexus and the mesorectal fascia are clearly shown on
MRI and thus permits an assessment of the distance
between the tumor and the potential circumferential
margin of total mesorectal excision, which is a relevant
factor for local recurrence of rectal carcinoma (7-9).
Lymph nodes with axes >0.5 cm in diameter in
MRI are considered malignant, but the size criteria are
not very accurate. The prediction of nodal metastases
can be improved by the signal intensity characteristics
and the border contour of lymph nodes instead of size
criteria (10). Almost all mesorectal lymph nodes visi-
ble on MRI were found at the level of the tumor or
within 5 cm proximal to the tumor (11).
The overall accuracy rates in T and N staging with
MRI is not very exact, in the study of Koh et al. (11)
47% and 64%, respectively. In T staging 47% of pa-
tients were overstaged and 6 % understaged. For each
histological T staging, the accuracy rate was as follows:
T0 was 20% (1/3 pat.), pT1 was 0% (0/3 pat.), pT2
was 29% (2/7 pat.), pT3 was 65% (13/20 pat.) and
pT4 100% (1/1 pat.). In our study lymph node invol-
vement was suspected in 81.4% of cases, confirmed in
in 8 cases microscopically after nCRT.
Peritumoral infiltrates with lymphocytes and va-
scular proliferation correlate with the extent of perile-
sional enhancement on MRIs. This picture may often
lead radiologists to overestimate stage. In fact, MRI
cannot really differentiate reactive fibrosis from tumor
infiltration or inflammatory changes in bowel wall
from tumor invasion after CRT (6, 12). For this rea-
sons chemoradiotherapy may reduce accuracy of resta-
ging of rectal carcinoma after adjuvant treatment (6,
13, 14). By contrast, pathological residual cancers be-
neath normal mural structure after chemoradiation
therapy may result in underestimation of rectal cancer
(6). To improve diagnostic discrimination particularly
T1 and T2 tumors EUS should always be routinely
added to initial tumor staging procedure (15). Accu-
racy of endoluminal ultrasound is reported to be 75-
94% for tumor penetration and 72-83% for nodal
metastases (16).
Surgery. Within the last years total mesorectal ex-
cision (TME) has gained a revolutionary impact on
the surgical therapy of cancer of the middle and the
lower third of the rectum. The term “total mesorectal
excision” is used by Heald first (17).The anatomy of
the fascia surrounding the rectum is already described
by Stelzner in 1962 (18). With the introduction of
TME local recurrence rates have been reliably decrea-
sed below 10% after curative resection (19, 20). Loco-
regional recurrence and distant metastases are the de-
terminants of long term survival in rectal cancer (21).
Additional prognostic relevant factors for local recur-
rence and survival are perirectal fat invasion of the tu-
mor, tumor-free circumference of the surgical speci-
men and nodal stage (22-24). Kapiteijn et al. empha-
sized the importance of a tumor-free circumference
without an infiltration of the perirectal tissue to less
than 2 mm to the fascia. Recurrences and distant me-
tastases occurred more often (37,6% vs. 12.7%,
p<0.001) and the 2-years cancer related survival was
decreased (67,9% vs. 90%, p<0.0001) (25, 26). 
In advanced (T4) rectal carcinomas it is often mo-
re difficult to get tumor-free resection conditions in
surgical treatment. In the Erlangen University Rectal
Cancer Study the regional lymph node status was
shown to be the most important factor for locoregio-
nal recurrence in advanced T4 rectal carcinoma. The
overall 3-year locoregional recurrence rate after curati-
ve resection was 12.7%. In patients without regional
lymph node involvement this was 2.3%, while it was
22.7% in patients with positive lymph nodes
(p=0.0055). In patients not having nCRT the local re-
currence rate was 17.2% at 3 years, in patients with
neoadjuvant or adjuvant RCT it was 5.4%. In the sa-
me study the 3-year cancer-related survival rate was ex-
cellent in patients without lymph node metastases
with 95% (vs. 54% in pN+ patients) and more favou-
rable in patients without tumor invasion in adjacent
organs with 76% (vs. 66%); nRCT reduced significan-
tly the risk for cancer-related death (27).
The Swedish Rectal Cancer Trial have shown redu-
ced local recurrence rates and improved overall survi-
val with a short-term preoperative 5x5 Gy regimen
compared with surgery alone. However, major radio-
and tumor biological shortcomings, among others the
short interval between radiation therapy and surgery,
which does not allow for significant tumor shrinkage
and improved sphincter preservation in low lying tu-
mors, and the high single dose, that may induce more
acute and late toxicity, are points of criticism (16).
Preoperative long-term chemoradiotherapy is re-
commended for rectal carcinoma when there is con-
cern that surgery alone may not be curative. The ef-
fects of downsizing by a neoadjuvant procedure is de-
scribed in up to 86% of cases and rates of complete re-
mission up to 44%. Rates of curative resection (R0) af-
ter neoadjuvant therapy range from 83 to about 90%
(28). The 3- and 5-year survival rates reach up to 82%
and 71%, respectively (27, 29). In our study patholo-
gic examination revealed a R0-resection without cir-
cumferential tumor in all cases, a infiltration of peri-
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rectal tissue to less than 2 mm to the circumference in
only 2 cases. Unfortunately unexpected liver metasasis
were intraoperatively diagnosed in 5 cases.
In T4 rectal carcinoma the treatment results with
surgery alone are not satisfactory. Even after extensive
surgery including resection of adjacent organs by par-
tial or total pelvic exenteration local failure remains hi-
gh and 5-year survival rates only reach 20-30%. After
nCRT disease-free resection margins can be achieved
in advanced (T4) rectal carcinoma in more than 80%
(18). A 6 weeks interval between nCRT and surgery
seems to be the optimal period for tumor shrinkage.
Stein et al. compared two groups with a 4-8 weeks in-
terval after completion of chemoradiotherapy and 10-
14 weeks after completion. There were no statistical
differences in perioperative morbidity, tumor down-
staging or pathologic complete response rate in both
groups. A longer interval between completion of
neoadjuvant chemoradiotherapy and resection may
not increase the tumor response (30).
In comparison of preoperative and adjuvant CRT
the rate of sphincter-preservation surgery is more than
doubled after preoperative chemoradiotherapy (39%
vs. 19%) in the study of Sauer et al. Postponing sur-
gery for a 6 week interval to allow tumor shrinkage
and recovery from side effects did not result in an in-
creased rate of surgical complications or an increased
incidence of tumor progression in comparison to the
adjuvant treatment group (20).
Complete response and regression rate. One ad-
vantage of long-term chemoradiotherapy is tumor sh-
rinkage and downstaging. Several reports show a
pathologic complete response rate in the range of 6 to
44% (6, 31). Kurt et al. described the tumor downsta-
ging rate in terms of the TNM classification in 58%
cases of their study and a complete histological respon-
se in 6% (31). In our patients we have seen regression
of more than 25% in nearly all cases (97.7%) and a
complete regression (grade 5) in 23.3% of cases.
To assess the colorectal cancer specimen after
neoadjuvant therapy, the pathologist has to be familiar
with the histological features induced by radioche-
motherapy. Performing a standardized pathological
procedure, different grades of tumor regression can be
observed and tumor staging should be standardized
using valid and reproducible criteria. An international
consensus does not exist. These criteria are recommen-
ded by Dworak et al., Wittekind et al. and the TNM
classification, using the ypTNM classification for as-
sessment of histological changes after neoadjuvant
treatment (4, 29, 32).
In most series significant downstaging of rectal
cancer was seen after treatment with nCRT. Although
this is usually described in terms of T stage and N sta-
ge, these may be inappropriate paramaters. Often a tu-
mor that is stage T3 or T4 tumor at preoperative CT
or transrectal ultrasound may still be a T3 or T4 tumor
following irradiation. However, in some of these tu-
mors, all that remains is a microscopic focus of adeno-
carcinoma in the subserosa with normal overlying mu-
cosa and intense fibrosis. Therefore Wheeler et al. (5)
recommended a pathologic staging system that measu-
res tumor regression of an irradiated rectal cancer, whi-
ch is worked out by Dworak et al. and Witteking et al.
and used in our study (4, 5, 32). In our series impro-
vement of the T-level could be noticed in 27 cases
(62.8%).
Complete regression of tumor seems not to be
equivalent to the absence of any vital tumor cells
within the surgical specimen but a rather a diagnostic
problem. Dworak used a very extensive pathological
technique to estimate the regression grading after
CRT. He embedded the whole suspicious area in pa-
raffin blocks for histological examination. Using this
technique he could not confirm a full histological re-
mission and found vital tumor cells in all cases. He
considered the mucinous substance in fibrotic not as a
residual tumor but rather a sign of therapeutic success.
The interpretation of lymph node involvement is mo-
re difficult since fibrotic changes can also be seen in
lymph nodes without radiochemotherapy. He found a
decreased number of lymph nodes in the specimen af-
ter radiochemotherapy (median 16 nodes) in compa-
rison to cases without therapy (median 30 nodes) (4).
We can confirm this observation with our data.
Nodal involvement is one of the relevant progno-
stic factors and central point of surgical treatment of
rectal cancer. In patients not given neoadjuvant the-
rapy, the risk of nodal metatasis increases with T stage,
ranges from 0% to 12% for pT1, 12-28% for pT2,
and 36% to 79% for pT3/T4 tumors. With a nCRT
the percentage of patients with positive lymph nodes
was only 1.8% in those of the rectal wall (pT0),
15.4% for pT1, 16.9% for pT2, 37.8% for pT3 and
33.3% for pT4 (12). Pucciarelli et al. concluded that
the risk of leaving mesorectal disease after nCRT is too
high for patients with residual tumor on the rectal
wall, the use non-radical surgical resection is not justi-
fied in patients with pT1 to pT4 tumors (33).
There are consequences for the surgeon. The preo-
perative radiochemotherapy seems not to be able to
eliminate all tumor cells, although tumor reduction is
achieved and operability improved. 
Conclusions
In our opinion the choice of operation (abdomino-
perineal extirpation vs. resection) should be made af-
ter the first staging procedure before starting neoadju-
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vant radiochemotherapy. A very small tumor size in
the preoperative restaging procedure after nCRT or
even the absence of a tumor corresponding to a com-
plete histological remission can not exclude the poten-
tial risk of local recurrences or lymph node involve-
ment of rectal cancer.
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